Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Криптогенная стеатотическая болезнь печени: клинико-инструментальное исследование - Журнал Терапевтический архив №12 Vario 2025
Криптогенная стеатотическая болезнь печени: клинико-инструментальное исследование
Гончаров А.А., Исаков В.А., Маев И.В. Криптогенная стеатотическая болезнь печени: клинико-инструментальное исследование. Терапевтический архив. 2025;97(12):987–993. DOI: 10.26442/00403660.2025.12.203453
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обоснование. В 2023 г. опубликована новая классификация заболеваний, проявляющихся стеатозом печени, в которой введено несколько новых нозологических единиц, включая криптогенную стеатотическую болезнь печени (КСБП).
Цель. Оценить распространенность КСБП в структуре заболеваний, проявляющихся стеатозом печени, и ее клинико-инструментальную характеристику.
Материалы и методы. Проведен ретроспективный анализ базы данных, включающей 4673 пациента, у которых оценивались стеатоз и фиброз печени. Критерии КСБП и других заболеваний печени основывались на рекомендациях Европейской ассоциации по изучению печени. Степени стеатоза и стадии фиброза печени определялись при помощи вибрационно контролируемой транзиентной эластографии печени с оценкой контролируемого параметра затухания ультразвукового сигнала. Состав тела пациентов изучался с помощью биоимпедансометрии. Проводилось исследование показателей жирового и углеводного обмена крови.
Результаты. Распространенность КСБП составила 0,8% (n=22) среди пациентов с выявленным стеатозом печени (n=2643). В группе КСБП по сравнению с группой стеатотической болезни печени, ассоциированной с метаболической дисфункцией, 3-я степень стеатоза печени S3 (27,3% против 67,6%; p<0,001) и стадии фиброза F2–F4 (9,1% против 29,3%; p=0,02) встречались достоверно реже. Группа КСБП отличалась от группы контроля (n=266) без стеатоза и фиброза печени индексом массы тела (медиана [Q1–Q3]: 24,1 [22,1–24,5] кг/м2 против 22,4 [20,7–23,7] кг/м2; p=0,008) за счет жировой массы (19,0 [16,6–26,7] кг против 16,4 [12,2–20,5] кг; p=0,03). Группа КСБП достоверно не отличалась от контрольной группы половозрастной структурой, показателями липидного профиля и углеводного обмена.
Заключение. КСБП является редким заболеванием. Пациенты с КСБП от лиц контрольной группы отличаются только жировой массой, при этом индекс массы тела у обеих групп находится в пределах нормальных значений. Показатели жирового и углеводного обмена в группе КСБП не отличаются от таковых у практически здоровых лиц.
Ключевые слова: криптогенная стеатотическая болезнь печени, стеатотическая болезнь печени, ассоциированная с метаболической дисфункцией, контролируемый параметр затухания
Aim. To assess the prevalence of CSLD within the spectrum of liver disorders associated with steatosis, and to describe its clinical and instrumental characteristics.
Materials and methods. A retrospective search was performed in the database of subjects underwent vibration-controlled transient liver elastography (n=4,673). Criteria of CSLD and other steatotic liver diseases were based on EASL guidelines. Liver stiffness and data of controlled attenuation parameter assessment were used to establish stage of liver fibrosis and degree of steatosis of the liver. Body composition was evaluated using bioimpedance analysis. Serum parameters of lipid and carbohydrate metabolism were assessed.
Results. CSLD was found in 22 (0.8%) of total number of subjects with the presence of hepatic steatosis (n=2,643). Advanced stages of fibrosis (F2–F4) and degree of steatosis (S3) were less prevalent in CSLD group compared to MASLD: 9.1% vs 29.3%; p=0.02; S3 27.3% vs 67.6%; p<0.001 accordingly. Compared to the control group (n=266) without steatosis and fibrosis, patients with CSLD had a greater body mass index (Median [Q1–Q3]: 24.1 [22.1–24.5] kg/m2 vs 22.4 [20.7–23.7] kg/m2; p=0.008), primarily due to greater fat mass (19.0 [16.6–26.7] kg vs 16.4 [12.2–20.5] kg; p=0.03). No significant difference was found between the CSLD and the control group on the demographic characteristics, serum lipid and carbohydrate metabolism parameters.
Conclusion. CSLD is a rare condition. Patients with CSLD had greater fat mass compared to the control group; however, both groups were characterized by normal values of body mass index, serum lipid and carbohydrate metaboliс parameters.
Keywords: cryptogenic steatotic liver disease, metabolic associated steatotic liver disease, сontrolled attenuation parameter
Цель. Оценить распространенность КСБП в структуре заболеваний, проявляющихся стеатозом печени, и ее клинико-инструментальную характеристику.
Материалы и методы. Проведен ретроспективный анализ базы данных, включающей 4673 пациента, у которых оценивались стеатоз и фиброз печени. Критерии КСБП и других заболеваний печени основывались на рекомендациях Европейской ассоциации по изучению печени. Степени стеатоза и стадии фиброза печени определялись при помощи вибрационно контролируемой транзиентной эластографии печени с оценкой контролируемого параметра затухания ультразвукового сигнала. Состав тела пациентов изучался с помощью биоимпедансометрии. Проводилось исследование показателей жирового и углеводного обмена крови.
Результаты. Распространенность КСБП составила 0,8% (n=22) среди пациентов с выявленным стеатозом печени (n=2643). В группе КСБП по сравнению с группой стеатотической болезни печени, ассоциированной с метаболической дисфункцией, 3-я степень стеатоза печени S3 (27,3% против 67,6%; p<0,001) и стадии фиброза F2–F4 (9,1% против 29,3%; p=0,02) встречались достоверно реже. Группа КСБП отличалась от группы контроля (n=266) без стеатоза и фиброза печени индексом массы тела (медиана [Q1–Q3]: 24,1 [22,1–24,5] кг/м2 против 22,4 [20,7–23,7] кг/м2; p=0,008) за счет жировой массы (19,0 [16,6–26,7] кг против 16,4 [12,2–20,5] кг; p=0,03). Группа КСБП достоверно не отличалась от контрольной группы половозрастной структурой, показателями липидного профиля и углеводного обмена.
Заключение. КСБП является редким заболеванием. Пациенты с КСБП от лиц контрольной группы отличаются только жировой массой, при этом индекс массы тела у обеих групп находится в пределах нормальных значений. Показатели жирового и углеводного обмена в группе КСБП не отличаются от таковых у практически здоровых лиц.
Ключевые слова: криптогенная стеатотическая болезнь печени, стеатотическая болезнь печени, ассоциированная с метаболической дисфункцией, контролируемый параметр затухания
________________________________________________
Aim. To assess the prevalence of CSLD within the spectrum of liver disorders associated with steatosis, and to describe its clinical and instrumental characteristics.
Materials and methods. A retrospective search was performed in the database of subjects underwent vibration-controlled transient liver elastography (n=4,673). Criteria of CSLD and other steatotic liver diseases were based on EASL guidelines. Liver stiffness and data of controlled attenuation parameter assessment were used to establish stage of liver fibrosis and degree of steatosis of the liver. Body composition was evaluated using bioimpedance analysis. Serum parameters of lipid and carbohydrate metabolism were assessed.
Results. CSLD was found in 22 (0.8%) of total number of subjects with the presence of hepatic steatosis (n=2,643). Advanced stages of fibrosis (F2–F4) and degree of steatosis (S3) were less prevalent in CSLD group compared to MASLD: 9.1% vs 29.3%; p=0.02; S3 27.3% vs 67.6%; p<0.001 accordingly. Compared to the control group (n=266) without steatosis and fibrosis, patients with CSLD had a greater body mass index (Median [Q1–Q3]: 24.1 [22.1–24.5] kg/m2 vs 22.4 [20.7–23.7] kg/m2; p=0.008), primarily due to greater fat mass (19.0 [16.6–26.7] kg vs 16.4 [12.2–20.5] kg; p=0.03). No significant difference was found between the CSLD and the control group on the demographic characteristics, serum lipid and carbohydrate metabolism parameters.
Conclusion. CSLD is a rare condition. Patients with CSLD had greater fat mass compared to the control group; however, both groups were characterized by normal values of body mass index, serum lipid and carbohydrate metaboliс parameters.
Keywords: cryptogenic steatotic liver disease, metabolic associated steatotic liver disease, сontrolled attenuation parameter
Полный текст
Список литературы
1. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. DOI:10.21037/tgh.2019.09.08
2. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. DOI:10.1186/s12944-024-02108-x
3. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313-9 [Maev IV, Andreev DN, Kucheryavy YuA. Prevalence of non-alcoholic fatty liver disease in Russia: a meta-analysis. Consilium Medicum. 2023;25(5):313-9 (in Russian)]. DOI:10.26442/20751753.2023.5.202155
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031
5. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-82. DOI:10.2337/dci24-0094
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. DOI:10.1016/j.jhep.2023.06.003
7. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-9. DOI:10.1097/HEP.0000000000000670
8. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-33. DOI:10.1111/liv.15695
9. Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment PharmacolTher. 2024;59(5):666-79. DOI:10.1111/apt.17849
10. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393-400. DOI:10.1097/HEP.0000000000000664
11. Wang SW, Hsieh TH, Cheng YM, et al. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Hepatol Int. 2024;18(3):943-51. DOI:10.1007/s12072-023-10624-8
12. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39(8):1636-47. DOI:10.1111/jgh.16554
13. Miwa T, Tajirika S, Imamura N, et al. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study. J Clin Med. 2024;13(4):1158. DOI:10.3390/jcm13041158
14. Baek JW, Yang YS, Jung KJ, et al. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2024;34(12):262329. DOI:10.1016/j.numecd.2024.09.001
15. Spencer-Sandino M, Godoy F, Huidobro L, et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann Hepatol. 2025;30(2):101919. DOI:10.1016/j.aohep.2025.101919
16. Kim A, Kang D, Choi SC, et al. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS One. 2024;19(3):e0301126. DOI:10.1371/journal.pone.0301126
17. Сасунова А.Н., Гончаров А.А., Гаппарова К.М., Исаков В.А. Взаимосвязь сахарного диабета и неалкогольной жировой болезни печени: клинико-инструментальное парное исследование. Терапевтический архив. 2024;96(8):764-70 [Sasunova AN, Goncharov AA, Gapparova KM, Isakov VA. Relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(8):764-70 (in Russian)]. DOI:10.26442/00403660.2024.08.202810
18. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30. DOI:10.1016/j.jhep.2016.12.022
19. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-9. DOI:10.1016/j.jhep.2010.07.033
20. Park KS, Lee DH, Lee J, et al. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complications. 2016;30(2):343-9. DOI:10.1016/j.jdiacomp.2015.10.014
21. Chaudry O, Grimm A, Friedberger A, et al. Magnetic Resonance Imaging and Bioelectrical Impedance Analysis to Assess Visceral and Abdominal Adipose Tissue. Obesity (Silver Spring). 2020;28(2):277-83. DOI:10.1002/oby.22712
22. Chan B, Yu Y, Huang F, Vardhanabhuti V. Towards visceral fat estimation at population scale: correlation of visceral adipose tissue assessment using three-dimensional cross-sectional imaging with BIA, DXA, and single-slice CT. Front Endocrinol (Lausanne). 2023;14:1211696. DOI:10.3389/fendo.2023.1211696
2. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. DOI:10.1186/s12944-024-02108-x
3. Maev IV, Andreev DN, Kucheryavy YuA. Prevalence of non-alcoholic fatty liver disease in Russia: a meta-analysis. Consilium Medicum. 2023;25(5):313-9 (in Russian). DOI:10.26442/20751753.2023.5.202155
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031
5. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-82. DOI:10.2337/dci24-0094
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. DOI:10.1016/j.jhep.2023.06.003
7. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-9. DOI:10.1097/HEP.0000000000000670
8. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-33. DOI:10.1111/liv.15695
9. Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment PharmacolTher. 2024;59(5):666-79. DOI:10.1111/apt.17849
10. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393-400. DOI:10.1097/HEP.0000000000000664
11. Wang SW, Hsieh TH, Cheng YM, et al. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Hepatol Int. 2024;18(3):943-51. DOI:10.1007/s12072-023-10624-8
12. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39(8):1636-47. DOI:10.1111/jgh.16554
13. Miwa T, Tajirika S, Imamura N, et al. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study. J Clin Med. 2024;13(4):1158. DOI:10.3390/jcm13041158
14. Baek JW, Yang YS, Jung KJ, et al. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2024;34(12):262329. DOI:10.1016/j.numecd.2024.09.001
15. Spencer-Sandino M, Godoy F, Huidobro L, et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann Hepatol. 2025;30(2):101919. DOI:10.1016/j.aohep.2025.101919
16. Kim A, Kang D, Choi SC, et al. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS One. 2024;19(3):e0301126. DOI:10.1371/journal.pone.0301126
17. Sasunova AN, Goncharov AA, Gapparova KM, Isakov VA. Relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(8):764-70 (in Russian). DOI:10.26442/00403660.2024.08.202810
18. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30. DOI:10.1016/j.jhep.2016.12.022
19. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-9. DOI:10.1016/j.jhep.2010.07.033
20. Park KS, Lee DH, Lee J, et al. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complications. 2016;30(2):343-9. DOI:10.1016/j.jdiacomp.2015.10.014
21. Chaudry O, Grimm A, Friedberger A, et al. Magnetic Resonance Imaging and Bioelectrical Impedance Analysis to Assess Visceral and Abdominal Adipose Tissue. Obesity (Silver Spring). 2020;28(2):277-83. DOI:10.1002/oby.22712
22. Chan B, Yu Y, Huang F, Vardhanabhuti V. Towards visceral fat estimation at population scale: correlation of visceral adipose tissue assessment using three-dimensional cross-sectional imaging with BIA, DXA, and single-slice CT. Front Endocrinol (Lausanne). 2023;14:1211696. DOI:10.3389/fendo.2023.1211696
2. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. DOI:10.1186/s12944-024-02108-x
3. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313-9 [Maev IV, Andreev DN, Kucheryavy YuA. Prevalence of non-alcoholic fatty liver disease in Russia: a meta-analysis. Consilium Medicum. 2023;25(5):313-9 (in Russian)]. DOI:10.26442/20751753.2023.5.202155
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031
5. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-82. DOI:10.2337/dci24-0094
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. DOI:10.1016/j.jhep.2023.06.003
7. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-9. DOI:10.1097/HEP.0000000000000670
8. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-33. DOI:10.1111/liv.15695
9. Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment PharmacolTher. 2024;59(5):666-79. DOI:10.1111/apt.17849
10. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393-400. DOI:10.1097/HEP.0000000000000664
11. Wang SW, Hsieh TH, Cheng YM, et al. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Hepatol Int. 2024;18(3):943-51. DOI:10.1007/s12072-023-10624-8
12. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39(8):1636-47. DOI:10.1111/jgh.16554
13. Miwa T, Tajirika S, Imamura N, et al. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study. J Clin Med. 2024;13(4):1158. DOI:10.3390/jcm13041158
14. Baek JW, Yang YS, Jung KJ, et al. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2024;34(12):262329. DOI:10.1016/j.numecd.2024.09.001
15. Spencer-Sandino M, Godoy F, Huidobro L, et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann Hepatol. 2025;30(2):101919. DOI:10.1016/j.aohep.2025.101919
16. Kim A, Kang D, Choi SC, et al. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS One. 2024;19(3):e0301126. DOI:10.1371/journal.pone.0301126
17. Сасунова А.Н., Гончаров А.А., Гаппарова К.М., Исаков В.А. Взаимосвязь сахарного диабета и неалкогольной жировой болезни печени: клинико-инструментальное парное исследование. Терапевтический архив. 2024;96(8):764-70 [Sasunova AN, Goncharov AA, Gapparova KM, Isakov VA. Relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(8):764-70 (in Russian)]. DOI:10.26442/00403660.2024.08.202810
18. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30. DOI:10.1016/j.jhep.2016.12.022
19. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-9. DOI:10.1016/j.jhep.2010.07.033
20. Park KS, Lee DH, Lee J, et al. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complications. 2016;30(2):343-9. DOI:10.1016/j.jdiacomp.2015.10.014
21. Chaudry O, Grimm A, Friedberger A, et al. Magnetic Resonance Imaging and Bioelectrical Impedance Analysis to Assess Visceral and Abdominal Adipose Tissue. Obesity (Silver Spring). 2020;28(2):277-83. DOI:10.1002/oby.22712
22. Chan B, Yu Y, Huang F, Vardhanabhuti V. Towards visceral fat estimation at population scale: correlation of visceral adipose tissue assessment using three-dimensional cross-sectional imaging with BIA, DXA, and single-slice CT. Front Endocrinol (Lausanne). 2023;14:1211696. DOI:10.3389/fendo.2023.1211696
________________________________________________
2. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. DOI:10.1186/s12944-024-02108-x
3. Maev IV, Andreev DN, Kucheryavy YuA. Prevalence of non-alcoholic fatty liver disease in Russia: a meta-analysis. Consilium Medicum. 2023;25(5):313-9 (in Russian). DOI:10.26442/20751753.2023.5.202155
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031
5. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-82. DOI:10.2337/dci24-0094
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. DOI:10.1016/j.jhep.2023.06.003
7. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-9. DOI:10.1097/HEP.0000000000000670
8. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-33. DOI:10.1111/liv.15695
9. Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment PharmacolTher. 2024;59(5):666-79. DOI:10.1111/apt.17849
10. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393-400. DOI:10.1097/HEP.0000000000000664
11. Wang SW, Hsieh TH, Cheng YM, et al. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Hepatol Int. 2024;18(3):943-51. DOI:10.1007/s12072-023-10624-8
12. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39(8):1636-47. DOI:10.1111/jgh.16554
13. Miwa T, Tajirika S, Imamura N, et al. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study. J Clin Med. 2024;13(4):1158. DOI:10.3390/jcm13041158
14. Baek JW, Yang YS, Jung KJ, et al. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2024;34(12):262329. DOI:10.1016/j.numecd.2024.09.001
15. Spencer-Sandino M, Godoy F, Huidobro L, et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann Hepatol. 2025;30(2):101919. DOI:10.1016/j.aohep.2025.101919
16. Kim A, Kang D, Choi SC, et al. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS One. 2024;19(3):e0301126. DOI:10.1371/journal.pone.0301126
17. Sasunova AN, Goncharov AA, Gapparova KM, Isakov VA. Relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(8):764-70 (in Russian). DOI:10.26442/00403660.2024.08.202810
18. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30. DOI:10.1016/j.jhep.2016.12.022
19. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-9. DOI:10.1016/j.jhep.2010.07.033
20. Park KS, Lee DH, Lee J, et al. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complications. 2016;30(2):343-9. DOI:10.1016/j.jdiacomp.2015.10.014
21. Chaudry O, Grimm A, Friedberger A, et al. Magnetic Resonance Imaging and Bioelectrical Impedance Analysis to Assess Visceral and Abdominal Adipose Tissue. Obesity (Silver Spring). 2020;28(2):277-83. DOI:10.1002/oby.22712
22. Chan B, Yu Y, Huang F, Vardhanabhuti V. Towards visceral fat estimation at population scale: correlation of visceral adipose tissue assessment using three-dimensional cross-sectional imaging with BIA, DXA, and single-slice CT. Front Endocrinol (Lausanne). 2023;14:1211696. DOI:10.3389/fendo.2023.1211696
Авторы
А.А. Гончаров*1, В.А. Исаков1, И.В. Маев2
1ФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи», Москва, Россия;
2ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия
*thisalexis@gmail.com
1Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia;
2Russian University of Medicine, Moscow, Russia
*thisalexis@gmail.com
1ФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи», Москва, Россия;
2ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия
*thisalexis@gmail.com
________________________________________________
1Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia;
2Russian University of Medicine, Moscow, Russia
*thisalexis@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.